Recorded February 11, 2021 | On-Demand Webinar
In September 2020, as part of its Safe Importation Action Plan, FDA issued a final rule allowing importation of certain prescription drugs from Canada (Pathway 1), along with a final guidance for importing prescription drugs originally intended for foreign markets (Pathway 2). In this webinar, panelists will take stock of the current state of drug importation, especially considering COVID-19 and the previous administration’s actions, and the potential impact on the US drug market. The discussion will include an in-depth review of both Pathway 1 and Pathway 2, how Canadian regulators and manufacturers have responded to the US plan, the possible risks of foreign drugs not approved by FDA, and the potential impact to US pricing, approvals, and innovation.